---
title: 'Funding Daily Summary: What Happened on November 11, 2026'
headline: VectorY secures €74.5 million for ALS gene therapy trial
description: Neobe raised $6.8 million for an engineered-bacteria cancer therapy,
  while Oyster closed a $60 million round for tau-degrader programs.
url: https://thebench.bio/news/funding/2026-11-11
topic: funding
date: '2026-11-11'
covers:
- '2026-11-11'
date_published: '2026-11-11T12:02:59Z'
date_modified: '2026-11-12T00:01:54Z'
tags:
- Funding
- Clinical
sources: 4
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on November 11, 2026

**VectorY secures €74.5 million for ALS gene therapy trial**

Neobe raised $6.8 million for an engineered-bacteria cancer therapy, while Oyster closed a $60 million round for tau-degrader programs.

## Today in brief

VectorY secured €74.5 million to fund its ALS gene therapy trial through final results and support other programs. [1] Neobe raised $6.8 million for preclinical work on its engineered-bacteria cancer program, and Oyster closed a $60 million round for tau-degrader development. [2] [3]

## VectorY raises €74.5 million for ALS trial

VectorY’s financing includes a €30 million loan from the European Investment Bank, backed by the European Commission’s InvestEU program. [1] The proceeds are intended to fund VTx-002 through final results from its Phase 1/2 PIONEER-ALS trial. [1]

The trial began dosing in February 2026 and plans to enroll 36 participants, up from 12 after VectorY cited fast recruitment and clinical-site activation. [1] It tests two doses of a one-time gene therapy designed to prompt cells in the central nervous system to produce antibodies against abnormal TDP-43. [1] Safety and tolerability are the trial’s main focus. Investigators are also monitoring biomarkers and measures of disease progression. [1]

The financing will also support VTx-003, a preclinical program targeting mutant huntingtin, and earlier programs for frontotemporal dementia and Alzheimer’s disease. [1] VTx-002’s safety and potential clinical benefit remain unproven. [1]

## Neobe raises $6.8 million for engineered-bacteria cancer program

Neobe raised a $6.8 million seed round led by ARC Ventures to advance NEO22 through preclinical development. [2] The company is developing nonpathogenic bacteria that produce enzymes inside tumors to break down part of the surrounding matrix. [2]

In a 2026 mouse study, the treatment reduced tumor stiffness and increased immune-cell entry. [2] Neobe reported that one dose combined with immunotherapy fully regressed tumors in a model of treatment-resistant triple-negative breast cancer. Mice later resisted re-exposure to the cancer. [2] The results are preclinical, and responses varied with tumor stiffness and the composition of the surrounding matrix. [2]

Neobe plans to seek an investigational new drug application in 2028 and said its total funding now exceeds $10.5 million. [2] Laura Chow joined as chief medical officer, responsible for clinical development. [2]

## Oyster closes $60 million round for tau-degrader work

Oyster Therapeutics closed a $60 million Series A-2 round led by 4BIO Capital, with Eli Lilly among the new investors. The company also adopted Oyster as its trading name. [3] The financing will support an oral degrader designed to remove pathological tau while preserving healthy forms of the protein. [3] [4]

Oyster’s SELFTAC platform uses a reversible linker intended to let smaller components cross cell membranes before joining into an active degrader. [4] Oyster says the approach could help degraders reach the brain. It still needs to demonstrate adequate brain exposure, selective tau clearance and clinical benefit. [4]

A sponsored research partnership with Massachusetts General Hospital will use patient-derived neuronal cell lines and methods to detect toxic forms of tau. [3] The financing will also support development of SELFTAC. [3]

## The day in numbers

- **€74.5 million**: VectorY’s new financing for its ALS trial and other programs, including a €30 million loan. [1]
- **$6.8 million**: Neobe’s seed round for preclinical development of NEO22. [2]
- **$60 million**: Oyster Therapeutics’ Series A-2 financing for tau-degrader programs and its SELFTAC platform. [3]

## Also published

- [Latest News on TechBio Revolution 🪴](<https://marinatalamanou.substack.com/p/latest-news-on-techbio-revolution-a19>), MetaphysicalCells
- [UK's Oyster Tx rebrands and raises $60m for Alzheimer's R&D](<https://pharmaphorum.com/news/uks-oyster-tx-rebrands-and-raises-60m-alzheimers-rd>), pharmaphorum
- [Neobe Plans to Stop Cancer Using Engineered Bacteria](<https://www.insideprecisionmedicine.com/topics/oncology/neobe-plans-to-stop-cancer-using-engineered-bacteria/>), Inside Precision Medicine
- [London biotech Oyster harvests $60M for tau-targeting brain drugs](<https://www.biopharmadive.com/news/oyster-venture-financing-tau-targeted-protein-degraders/874160/>), BioPharma Dive

## Sources

1. [VectorY secures €74.5M to advance ALS gene therapy trial](<https://european-biotechnology.com/latest-news/vectory-secures-e74-5m-to-advance-als-gene-therapy-trial/>), European Biotechnology, 2026-11-11
2. [Neobe raises $6.8M to break tumor barriers with bacteria](<https://european-biotechnology.com/latest-news/neobe-raises-6-8m-to-break-tumor-barriers-with-bacteria/>), European Biotechnology, 2026-11-10
3. [Lilly-backed Oyster Therapeutics raises $60m for neurological degraders](<https://www.pharmaceutical-technology.com/news/oyster-60m-neurological-degraders-pipeline/>), Pharmaceutical Technology, 2026-11-11
4. [Oyster Therapeutics raises $60M to bring Alzheimer’s tau degrader to clinic](<https://european-biotechnology.com/latest-news/oyster-therapeutics-raises-60m-to-bring-alzheimers-tau-degrader-to-clinic/>), European Biotechnology, 2026-11-10

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://european-biotechnology.com/latest-news/vectory-secures-e74-5m-to-advance-als-gene-therapy-trial/>
[2]: <https://european-biotechnology.com/latest-news/neobe-raises-6-8m-to-break-tumor-barriers-with-bacteria/>
[3]: <https://www.pharmaceutical-technology.com/news/oyster-60m-neurological-degraders-pipeline/>
[4]: <https://european-biotechnology.com/latest-news/oyster-therapeutics-raises-60m-to-bring-alzheimers-tau-degrader-to-clinic/>
